Robert E. Davis, SVP, Chief Scientific Officer at Intra-Cellular Therapies, Inc. (ITCI), sold 650 shares at $15.00 ($10K) on 2017-12-05, disclosed to the SEC on 2017-12-06.
Scheduled sale ($10k) by SVP, Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| Filing → |
| ITCI | SELL | 2018-12-07 | $12K | — | Filing → |
| ITCI | SELL | 2018-01-05 | $17K | — | Filing → |